FRANKFURT (dpa-AFX Broker) - Deutsche Bank Research has downgraded Evotec from "Buy" to "Hold" and lowered the price target from 12 to 10 euros. In his outlook published on Thursday, analyst Falko Friedrichs expects a meagre quarterly report and sees the drug discovery company's annual targets at risk. He fears that the target for the adjusted operating result (EBITDA) will be cut to around 70 million euros, compared to the consensus of 91 million euros./ag/edh

Publication of the original study: 11.07.2024 / time not specified in study / CET

First dissemination of the original study: 11.07.2024 / 08:00 / CET